Edition:
United Kingdom

Biotechnology & Medical Research

Janssen receives approval for Tremfya in Europe - Morphosys

Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is ‍entitled to royalties on net sales of Janssen's Tremfya​.

9:19am GMT

Xintela Q3 pretax loss widens to SEK 4.9 mln

Nov 23 (Reuters) - XINTELA AB ::Q3 PRETAX LOSS SEK 4.9 MILLION VERSUS LOSS SEK 3.0 MILLION YEAR AGO.

7:31am GMT

Aytu Bioscience files for mixed shelf of upto $100 mln

Nov 22 (Reuters) - Aytu Bioscience Inc :Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing.

Wednesday, 22 Nov 2017

CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017

Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​.

Wednesday, 22 Nov 2017

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.